In this conversation, Tina Eden, R.N., CEO of Virginia Gay Hospital, and Jacinda Bunch, Ph.D., R.N., assistant professor at ...

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic ...

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...

First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries– Investigator-Initiated (IIT) funded pancreatic and ...

| Servier is committing to rare neurology for the long term, using focused science and strategic collaborations to bring new ...

Challenges remain, like regulatory hurdles and funding, but our team's grit and your support as shareholders make me ...

The company also announced the appointment of Han Lee, Ph.D., as co-chief executive officer (CEO), and the U.S. Food and Drug ...

Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...

Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show that cancer drug treatments can be safely and effectively personalized based ...

Wayne State University is seeking veterans with post traumatic stress disorder to participate in a study testing the impacts ...